A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the "Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Wall Street major averages closed significantly higher on Friday, despite softer-than-expected inflation data, and consumer sentiment dropping to the second-lowest on record. Week-to-date, the U.S.